NZ594829A - Methods of using sns-595 for treatment of cancer subjects with reduced brca2 activity - Google Patents
Methods of using sns-595 for treatment of cancer subjects with reduced brca2 activityInfo
- Publication number
- NZ594829A NZ594829A NZ594829A NZ59482910A NZ594829A NZ 594829 A NZ594829 A NZ 594829A NZ 594829 A NZ594829 A NZ 594829A NZ 59482910 A NZ59482910 A NZ 59482910A NZ 594829 A NZ594829 A NZ 594829A
- Authority
- NZ
- New Zealand
- Prior art keywords
- sns
- treatment
- methods
- cancer subjects
- brca2 activity
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 102000052609 BRCA2 Human genes 0.000 abstract 2
- 108700020462 BRCA2 Proteins 0.000 abstract 2
- 101150008921 Brca2 gene Proteins 0.000 abstract 2
- XZAFZXJXZHRNAQ-STQMWFEESA-N vosaroxin Chemical compound C1[C@H](OC)[C@@H](NC)CN1C1=CC=C2C(=O)C(C(O)=O)=CN(C=3SC=CN=3)C2=N1 XZAFZXJXZHRNAQ-STQMWFEESA-N 0.000 abstract 2
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000035772 mutation Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pathology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15644909P | 2009-02-27 | 2009-02-27 | |
| US17001309P | 2009-04-16 | 2009-04-16 | |
| PCT/US2010/025737 WO2010099526A1 (en) | 2009-02-27 | 2010-03-01 | Methods of using sns-595 for treatment of cancer subjects with reduced brca2 activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ594829A true NZ594829A (en) | 2013-09-27 |
Family
ID=42224275
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ594829A NZ594829A (en) | 2009-02-27 | 2010-03-01 | Methods of using sns-595 for treatment of cancer subjects with reduced brca2 activity |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US20120148564A1 (enExample) |
| EP (2) | EP2400959A1 (enExample) |
| JP (2) | JP5936862B2 (enExample) |
| KR (2) | KR20110132400A (enExample) |
| CN (2) | CN104688732A (enExample) |
| AU (2) | AU2010217796B2 (enExample) |
| CA (1) | CA2753261A1 (enExample) |
| IL (1) | IL214784A0 (enExample) |
| MX (1) | MX348412B (enExample) |
| NZ (1) | NZ594829A (enExample) |
| RU (1) | RU2558835C2 (enExample) |
| SG (2) | SG10201400258SA (enExample) |
| WO (1) | WO2010099526A1 (enExample) |
| ZA (1) | ZA201106199B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2005222622B2 (en) | 2004-03-15 | 2011-04-07 | Dainippon Sumitomo Pharma Co., Ltd. | SNS-595 and methods of using the same |
| AU2008317400B2 (en) | 2007-10-22 | 2014-10-02 | Sunesis Pharmaceuticals, Inc. | Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino) -1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3- carboxylic acid in combination therapy |
| EP3284745A1 (en) | 2008-12-31 | 2018-02-21 | Sunesis Pharmaceuticals, Inc. | Composition of (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid |
| CN104688732A (zh) * | 2009-02-27 | 2015-06-10 | 逊尼希思制药公司 | 利用sns-595治疗具有降低的brca2活性的癌症对象的方法 |
| UA110465C2 (en) | 2009-09-04 | 2016-01-12 | Sunesis Pharmaceutecals Inc | Stable sns-595 composition |
| US8470817B2 (en) | 2009-10-26 | 2013-06-25 | Sunesis Pharmaceuticals, Inc. | Compounds and methods for treatment of cancer |
| WO2023110045A1 (en) | 2021-12-15 | 2023-06-22 | Y-Mabs Therapeutics, Inc. | Scfv and antibodies with reduced multimerisation |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6024A (en) * | 1849-01-09 | Cast-iron gar-wheel | ||
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| ATE209645T1 (de) | 1994-06-14 | 2001-12-15 | Dainippon Pharmaceutical Co | Neue verbindung, verfahren zu ihrer herstellung und antitumormittel |
| JPH10173986A (ja) | 1996-12-16 | 1998-06-26 | Sony Corp | 移動体撮影装置 |
| CA2547077C (en) * | 2003-12-01 | 2015-11-03 | Kudos Pharmaceuticals Limited | Dna damage repair inhibitors for treatment of cancer |
| AU2005222622B2 (en) | 2004-03-15 | 2011-04-07 | Dainippon Sumitomo Pharma Co., Ltd. | SNS-595 and methods of using the same |
| AU2006287149B2 (en) * | 2005-09-02 | 2013-05-23 | Sunesis Pharmaceuticals, Inc. | Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer |
| MX2008015775A (es) | 2006-06-12 | 2009-04-17 | Sunesis Pharmaceuticals Inc | Compuestos y composiciones para tratamiento de cancer. |
| US7790274B2 (en) | 2006-08-02 | 2010-09-07 | High Impact Technology, Llc | Layered panel structure including self-bonded thermoformable and non-thermoformable layer materials |
| EP2155897A2 (en) * | 2007-03-30 | 2010-02-24 | Source Precision Medicine, Inc. d/b/a Source MDX. | Gene expression profiling for identification, monitoring, and treatment of prostate cancer |
| CN104688732A (zh) * | 2009-02-27 | 2015-06-10 | 逊尼希思制药公司 | 利用sns-595治疗具有降低的brca2活性的癌症对象的方法 |
-
2010
- 2010-03-01 CN CN201410799921.9A patent/CN104688732A/zh active Pending
- 2010-03-01 SG SG10201400258SA patent/SG10201400258SA/en unknown
- 2010-03-01 EP EP10707173A patent/EP2400959A1/en not_active Withdrawn
- 2010-03-01 RU RU2011139323/15A patent/RU2558835C2/ru not_active IP Right Cessation
- 2010-03-01 JP JP2011552217A patent/JP5936862B2/ja not_active Expired - Fee Related
- 2010-03-01 KR KR1020117022340A patent/KR20110132400A/ko not_active Ceased
- 2010-03-01 US US13/203,718 patent/US20120148564A1/en not_active Abandoned
- 2010-03-01 AU AU2010217796A patent/AU2010217796B2/en not_active Ceased
- 2010-03-01 MX MX2011008994A patent/MX348412B/es active IP Right Grant
- 2010-03-01 CN CN2010800172031A patent/CN102405045A/zh active Pending
- 2010-03-01 WO PCT/US2010/025737 patent/WO2010099526A1/en not_active Ceased
- 2010-03-01 CA CA2753261A patent/CA2753261A1/en not_active Abandoned
- 2010-03-01 NZ NZ594829A patent/NZ594829A/xx not_active IP Right Cessation
- 2010-03-01 SG SG2011061512A patent/SG173855A1/en unknown
- 2010-03-01 EP EP17179348.2A patent/EP3287126A1/en not_active Withdrawn
- 2010-03-01 KR KR1020177010758A patent/KR20170046193A/ko not_active Ceased
-
2011
- 2011-08-22 IL IL214784A patent/IL214784A0/en unknown
- 2011-08-23 ZA ZA2011/06199A patent/ZA201106199B/en unknown
-
2014
- 2014-09-03 US US14/476,606 patent/US20150202189A1/en not_active Abandoned
-
2015
- 2015-03-24 JP JP2015060900A patent/JP2015145396A/ja active Pending
- 2015-07-30 AU AU2015207901A patent/AU2015207901A1/en not_active Abandoned
-
2016
- 2016-08-10 US US15/233,860 patent/US20170182015A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2010217796B2 (en) | 2015-04-30 |
| ZA201106199B (en) | 2012-10-31 |
| JP2012523376A (ja) | 2012-10-04 |
| RU2558835C2 (ru) | 2015-08-10 |
| KR20170046193A (ko) | 2017-04-28 |
| AU2010217796A1 (en) | 2011-09-15 |
| JP2015145396A (ja) | 2015-08-13 |
| SG173855A1 (en) | 2011-09-29 |
| RU2011139323A (ru) | 2013-04-10 |
| KR20110132400A (ko) | 2011-12-07 |
| US20170182015A1 (en) | 2017-06-29 |
| CN104688732A (zh) | 2015-06-10 |
| US20150202189A1 (en) | 2015-07-23 |
| CA2753261A1 (en) | 2010-09-02 |
| JP5936862B2 (ja) | 2016-06-22 |
| SG10201400258SA (en) | 2014-05-29 |
| CN102405045A (zh) | 2012-04-04 |
| MX2011008994A (es) | 2011-09-15 |
| IL214784A0 (en) | 2011-11-30 |
| MX348412B (es) | 2017-06-12 |
| WO2010099526A1 (en) | 2010-09-02 |
| AU2015207901A1 (en) | 2015-08-20 |
| US20120148564A1 (en) | 2012-06-14 |
| EP3287126A1 (en) | 2018-02-28 |
| EP2400959A1 (en) | 2012-01-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ594829A (en) | Methods of using sns-595 for treatment of cancer subjects with reduced brca2 activity | |
| IL248049A0 (en) | Sns-595 and methods of using the same | |
| WO2009075841A3 (en) | Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders | |
| WO2008016702A3 (en) | Combined use of (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1(2-thiazolyl)-1,8-naphthyridine-3-carboxylic | |
| MX2019005130A (es) | Inhibidores de dpp-iv, tales como la linagliptina, y composiciones farmaceuticas o combinaciones que comprenden los mismos, para usarse en el tratamiento de pacientes diabeticos tipificados geneticamente. | |
| SG148177A1 (en) | Novel cis-imidazolines | |
| MX2010004350A (es) | Metodos de uso del acido (+)-1,4-dihidro-7-[(3s,4s)]-3-metoxi-4-(m etilamino)-1-pirrolidinil-4-oxo-1-(2-tiazolil)-1, 8-naftiridina-3-carboxilico en terapias de combinacion. | |
| AU2011274192A8 (en) | Heterocyclic alkynyl benzene compounds and medical compositions and uses thereof | |
| NZ600874A (en) | Fluorinated derivatives of deferiprone | |
| BRPI0916356A2 (enExample) | ||
| TW200700093A (en) | Pharmaceutical composition for the treatment of cancer | |
| WO2010093727A8 (en) | Quinazolinones as prolyl hydroxylase inhibitors | |
| MY148258A (en) | Phenylamino-benzoxazole substituted carboxylic acids, method for their production and use thereof as medicaments | |
| MX2010005631A (es) | Nuevos compuestos de hidrocarburo ciclicos para el tratamiento de enfermedades. | |
| TN2011000234A1 (en) | Heterocyclically substituted aryl compounds as hif inhibitors | |
| WO2011127333A3 (en) | Compounds for treating disease, for administering, and for pharmaceutical compositions | |
| MX2013010770A (es) | Tratamiento de tumores solidos. | |
| GEP20186880B (en) | 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease | |
| MX2009007247A (es) | Metodo para el tratamiento de afecciones asociadas con actividad aumentada de 5-lipoxigenasa y/o leucotrienos. | |
| MX2009013501A (es) | Compuestos piperidinicos y sus usos. | |
| PH12014502448A1 (en) | Pharmaceutical combinations for the treatment of metabolic disorders | |
| JP2009539994A5 (enExample) | ||
| GB0718878D0 (en) | Photodynamic Theraphy and diagnosis | |
| WO2010078294A8 (en) | Method of preparing (+)-1,4-dihydro-7-[(3s,4s)-3methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid | |
| PL1610787T3 (pl) | Synergiczna kombinacja zawierająca roflumilast i środek antycholinergiczny wybrany z soli tiotropium do leczenia chorób układu oddechowego |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 01 MAR 2017 BY CPA GLOBAL Effective date: 20140116 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 01 MAR 2018 BY CPA GLOBAL Effective date: 20170113 |
|
| LAPS | Patent lapsed |